Quarterly intravenous ibandronate for postmenopausal osteoporosis (Q37346101)

19 August 2017

1 reference

title

Quarterly intravenous ibandronate for postmenopausal osteoporosis (English)

1 reference

19 August 2017

0 references

Ronald D Emkey

1

1 reference

19 August 2017

publication date

1 May 2008

1 reference

19 August 2017

1 reference

19 August 2017

volume

4

1 reference

19 August 2017

issue

3

1 reference

19 August 2017

page(s)

219-228

1 reference

Epidemiology and outcomes of osteoporotic fractures

19 August 2017

cites work

1 reference

https://api.crossref.org/works/10.2217%2F17455057.4.3.219

Mortality, disability, and nursing home use for persons with and without hip fracture: a population-based study

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F17455057.4.3.219

Incidence and economic burden of osteoporosis-related fractures in the United States, 2005-2025.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F17455057.4.3.219

What is the role of DXA, QUS and bone markers in fracture prediction, treatment allocation and monitoring?

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F17455057.4.3.219

Effect of risedronate on the risk of hip fracture in elderly women. Hip Intervention Program Study Group.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F17455057.4.3.219

The efficacy and tolerability of risedronate once a week for the treatment of postmenopausal osteoporosis

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F17455057.4.3.219

Efficacy and tolerability of once-monthly oral ibandronate in postmenopausal osteoporosis: 2 year results from the MOBILE study

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F17455057.4.3.219

Safety considerations with bisphosphonates for the treatment of osteoporosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F17455057.4.3.219

Update on osteoporosis management in long-term care: focus on bisphosphonates

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F17455057.4.3.219

Once-yearly zoledronic acid for treatment of postmenopausal osteoporosis

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F17455057.4.3.219

Renal Failure with the Use of Zoledronic Acid

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F17455057.4.3.219

Intravenous ibandronate: in the treatment of osteoporosis

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F17455057.4.3.219

Ibandronate: a clinical pharmacological and pharmacokinetic update

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F17455057.4.3.219

Recent advances in understanding the mechanism of action of bisphosphonates

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F17455057.4.3.219

An update on biomarkers of bone turnover and their utility in biomedical research and clinical practice

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F17455057.4.3.219

Monitoring osteoporosis therapy: bone mineral density, bone turnover markers, or both?

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F17455057.4.3.219

Insufficiently dosed intravenous ibandronate injections are associated with suboptimal antifracture efficacy in postmenopausal osteoporosis

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F17455057.4.3.219

Efficacy and safety of ibandronate given by intravenous injection once every 3 months

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F17455057.4.3.219

Effects of oral ibandronate administered daily or intermittently on fracture risk in postmenopausal osteoporosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F17455057.4.3.219

Two-year efficacy and tolerability of risedronate once a week for the treatment of women with postmenopausal osteoporosis

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F17455057.4.3.219

Progression of efficacy with ibandronate: a paradigm for the development of new bisphosphonates

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F17455057.4.3.219

Accretion of bone quantity and quality in the developing mouse skeleton

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F17455057.4.3.219

Narrative [corrected] review: bisphosphonates and osteonecrosis of the jaws

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F17455057.4.3.219

Alternative bisphosphonate targets and mechanisms of action

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F17455057.4.3.219

Improving the outcome of established therapies for osteoporosis by adding the active D-hormone analog alfacalcidol

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F17455057.4.3.219

The effects of parathyroid hormone and alendronate alone or in combination in postmenopausal osteoporosis

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F17455057.4.3.219

Effects of teriparatide, alendronate, or both on bone turnover in osteoporotic men.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F17455057.4.3.219

One year of alendronate after one year of parathyroid hormone (1-84) for osteoporosis

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F17455057.4.3.219

Intravenous ibandronate injections given every three months: a new treatment option to prevent bone loss in postmenopausal women

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F17455057.4.3.219

Denosumab in postmenopausal women with low bone mineral density

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F17455057.4.3.219

Wnt but not BMP signaling is involved in the inhibitory action of sclerostin on BMP-stimulated bone formation

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F17455057.4.3.219

Mechanical stimulation of bone in vivo reduces osteocyte expression of Sost/sclerostin

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F17455057.4.3.219

FRAX and the assessment of fracture probability in men and women from the UK

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F17455057.4.3.219

Implications of absolute fracture risk assessment for osteoporosis practice guidelines in the USA.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F17455057.4.3.219

Intravenous ibandronate injections in postmenopausal women with osteoporosis: One-year results from the dosing intravenous administration study

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F17455057.4.3.219

21 January 2018

Identifiers

DOI

10.2217/17455057.4.3.219

1 reference

19 August 2017

1 reference